Issue link: https://www.e-digitaleditions.com/i/1543258
22 February 2026 Inhalation 58. Human respiratory tract model for radiological protection—ICRP 66. Annals of the International Commission on Radiological Protection (ICRP) 24: 492 (1994). 59. Legh-Land, V. et al. e missing link: Coupling Next Generation Impactor studies with an in-silico pulmonary deposition model. Drug Delivery to the Lungs (Edinburgh, 2024). 60. Nimmano, N. et al. Comparison of efficacies of full and abbreviated cascade impactors in aero- sol characterization of nebulized salbutamol sulfate produced by a jet nebulizer. Pharmacia 68: 899-905 (2021). 61. Ammari, W. G. et al. Delivered lung dose and aerodynamic particle size distribution of salbutamol pressurized metered dose inhaler after living under patients' realistic retention environments. Journal of Aerosol Medicine and Pulmonary Drug Delivery 32: 386-395 (2019). 62. Ohar, J. A. et al. In vitro effect of different airflow rates on the aerosol properties of nebulized glyco- pyrrolate in the eflow closed system and tiotropium delivered in the HandiHaler ® . Pulmonary erapy doi:10.6084/m9.figshare.12746840. 63. Ammari, W. G. et al. Evaluation of patients' real- world post-dispensing use and storage environments of tiotropium bromide Respimat ® soft mist inhaler on its in vitro dose delivery and lung deposition. Pul- monary Pharmacology & erapeutics 58: 101829 (2019). 64. Newman, S. P. Fine particle fraction: e good and the bad. Journal of Aerosol Medicine and Pul- monary Drug Delivery 35: 2-10 (2022). Victoria Legh-Land, PhD, COO, Microsol Ltd. Dan Hardy, PhD, CEO, Microsol Ltd. Katja Petkau- Milroy, PhD, Formulation Lead, Microsol Ltd. Mark Sanders, MBA, PhD Candidate, University of Hert- fordshire and Commercial Advisor, Microsol Ltd. Cor- responding author: Victoria Legh-Land, PhD, Microsol Ltd. Engine Shed, Station Approach, Redcliffe, Bristol, BS1 6QH, United Kingdom, toria@microsolscience. com, www.microsolscience.com. 45. Sou, T. et al. Model-based drug development in pulmonary delivery: Pharmacokinetic analysis of novel drug candidates for treatment of Pseudomonas aeruginosa lung infection. Journal of Pharmaceutical Sciences 108: 630-640 (2019). 46. Bäckman, P. et al. Advances in experimental and mechanistic computational models to under- stand pulmonary exposure to inhaled drugs. Euro- pean Journal of Pharmaceutical Sciences 113: 41-52 (2018). 47. Borghardt, J. M. et al. Pharmacometric mod- els for characterizing the pharmacokinetics of orally inhaled drugs. AAPS Journal 17: 853-870 (2015). 48. Olsson, B. et al. Mimetikos Preludium™: A new pharma-friendly aerosol drug deposition calculator. Respiratory Drug Delivery (2018). 49. Stass, H. et al. Inhalation of a dry powder cip- rofloxacin formulation in healthy subjects: A phase I study. Clinical Drug Investigation 33: 419-427 (2013). 50. Lippert, J. et al. Open Systems Pharmacology Community—An open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. CPT: Pharmacometrics & Systems Pharmacology 8: 878-882. Preprint at https://doi.org/10.1002/psp4.12473 (2019). 51. Haddrell, A. E. et al. Dynamics of aerosol size during inhalation: Hygroscopic growth of commer- cial nebulizer formulations. International Journal of Pharmaceutics 463: 50-61 (2014). 52. Duke, D. Environmentally friendly metered dose inhaler propellants: Challenges for inhaler design. Inhalation 18(1) 10-17 (2024). 53. Duke, D. J. et al. In-vitro evaluation of solution pressurised metered dose inhaler sprays with low- GWP propellants. Pharmaceutical Research 42: 385- 400 (2025). 54. Wang, H. et al. Understanding the performance of pressurized metered dose inhalers formulated with low global warming potential propellants. Aerosol Science and Technology 58(9): 1-19 (2024). 55. Hardy, D. et al. A method for exploring the evap- oration of pMDIs propellant droplets with micro- second time resolution. Drug Delivery to the Lungs (Edinburgh, 2024). 56. Legh-land, V. et al. Water uptake by evaporat- ing pMDI aerosol prior to inhalation affects both regional and total deposition in the respiratory sys- tem. Pharmaceutics 13(7): 941 (2021). 57. Newman, S. P. Spacer devices for metered dose inhalers. Clinical Pharmacokinetics 43: 349-360 (2004).